With Funds from R&D Partners, Traversa Advances In-House Programs

However, the company will most likely require an additional infusion of capital before it can move any of its programs into the clinic, Traversa President and CEO Hans Petersen said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.